SOURCE: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. Logo

January 16, 2014 10:19 ET

Matinas BioPharma Announces Presentation at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22, 2014

BEDMINSTER, NJ--(Marketwired - January 16, 2014) - Matinas BioPharma Holdings, Inc., an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular conditions, announced today that the Company will be presenting at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida.

Roelof Rongen, Chief Executive Officer, will present a Company overview on Wednesday, January 22, 2014 at 10:00 am Eastern Time. Mr. Rongen's presentation will include the Company's business outlook for 2014, an overview of the development of its lead product candidate, MAT9001, and key milestones expected over the next 12 months.

About MAT9001
MAT9001 is a proprietary prescription-grade omega-3 fatty acid-based composition, comprised of a complex mixture of omega-3 fatty acids which has been developed for therapeutic applications, with severe hypertriglyceridemia (TG greater than 500 mg/dL) as the lead indication. Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and conduct its first human study in mid-2014. The Company believes that the its development program and related clinical investigations may yield a stronger therapeutic profile compared to existing therapies, characterized most importantly by MAT9001's differentiating mechanistic features associated with its unique composition and enhanced potency. 

About Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a development stage, privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of cardiovascular conditions. The Company's lead product candidate, MAT9001, is designed for treatment of severe hypertriglyceridemia (TG greater than 500 mg/dl). The Matinas BioPharma management team brings a cumulative multi-decade omega-3 pharmaceutical experience to the Company, providing a unique perspective and capability for the development of the next generation of omega-3-fatty acid-based pharmaceutical products. For more information, please visit www.matinasbiopharma.com.

About Noble Financial
Noble Financial Capital Markets was established in 1984; 2014 marks its 30th Anniversary. Noble Financial is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in Boston, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 120-150 presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com.

Forward Looking Statements: This release contains "forward-looking statements", including those related to the Company's strategic focus and the future development MAT9001. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Source: Matinas BioPharma Holdings, Inc.

Contact Information

  • Investor and Media Contact:
    Jenene Thomas
    Investor Relations and Corporate Communications Advisor
    Jenene Thomas Communications, LLC
    Phone: +1 (908) 938-1475 
    Email: Jthomas@matinasbiopharma.com